Key Highlights

  • EBOS Group (ASX:EBO) increased FY26 Revenue 9.9% to $13.5 billion, while Underlying EBITDA rose 5.0% to $614 million.
  • Underlying NPAT declined 3.1% to $250 million, reflecting higher depreciation, Amortisation and financing costs following the group's infrastructure Investment program.
  • Animal Care revenue increased 34.6% and Underlying EBITDA rose 11.6%, while Healthcare revenue increased 8.5% and EBITDA grew 3.2%.
  • EBOS completed its four-year, $360 million distribution centre renewal program and expects FY27 Capital Expenditure to reduce to approximately $100 million.

EBOS Group (ASX:EBO) shares are down 47.58% over the past year, despite a 0.92% gain today to AUD 18.74, after the healthcare distributor reported higher revenue but lower Underlying Profit for FY26.

What's Behind the Longer-Term Move

Revenue for the year to 30 June 2026 increased 9.9% to $13.5 billion, with Underlying EBITDA up 5.0% to $614 million. However, Underlying NPAT declined 3.1% to $250 million as depreciation, amortisation and financing costs rose following the group's infrastructure investment program. Underlying EPS fell 7.3% to 121.7 cents.

Healthcare remained the largest contributor, with revenue up 8.5% to $12.6 billion, though EBITDA Margin slipped to 4.1% from 4.3%. Animal Care was the standout, with revenue up 34.6% to $907 million and EBITDA up 11.6% to $138 million. Medical Technology revenue rose 5.5% (8.4% constant-currency).

Investment Cycle Completed

EBOS finished its four-year, $360 million distribution centre renewal program in FY26, shifting focus toward utilisation and productivity. Leverage ended at 2.1x, and return on capital employed declined to 12.8% from 13.0%.

Should You Keep EBO on Your Radar?

The final Dividend was held at NZ61.5 cents per share. FY27 Underlying EBITDA guidance is $635–655 million, with capital expenditure expected to fall to approximately $100 million as the investment cycle winds down.